Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.35 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.30 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.30 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2600074 | 0.83 | HDAC6 (0.39) | HDAC6CYP11B1CYP11B2L3MBTL1BRD4 | |
| SCHEMBL21654371 | 0.81 | PRMT6 (0.38) | KMT2A | |
| SCHEMBL21654295 | 0.77 | POLB (0.31) | — | |
| SCHEMBL15314018 | 0.74 | HDAC6 (0.39) | HDAC6CYP11B1CYP11B2BRD4ALDH1A1 | |
| SCHEMBL18869442 | 0.70 | HDAC6 (0.39) | HDAC6CYP11B1CYP11B2L3MBTL1ALDH1A1 | |
| SCHEMBL22022356 | 0.70 | HDAC6 (0.36) | HDAC6CYP11B1CYP11B2BRD4ALDH1A1 | |
| SCHEMBL6281994 | 0.70 | CYP2C19 (0.48) | L3MBTL1MEN1KMT2A | |
| SCHEMBL8445207 | 0.70 | HDAC6 (0.41) | HDAC6CYP11B1CYP11B2L3MBTL1BRD4 | |
| SCHEMBL2789093 | 0.70 | CYP2C19 (0.48) | L3MBTL1MEN1KMT2A | |
| SCHEMBL27708181 | 0.70 | HDAC6 (0.41) | HDAC6CYP11B1CYP11B2BRD4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10543222-B2 | Therapy for inhibition of single-stranded RNA virus replication | REDHILL BIOPHARMA LTD. (IL) | 2020-01-28 | — | — | US | disclosed |
| US-8063248-B2 | 3-(4-Chloro-phenyl)-adamantane-1-carboxylic acidisopropylamide; antiproliferative, antiinflammatory agent, angiogenesis inhibitor; sphingolipid-derived signaling pathway; coupling acid or acylhalide of phenyl-adamantane derivatives with aminoalkyl-pyridine | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10543222-B2 | Therapy for inhibition of single-stranded RNA virus replication | RNMT, EIF2AK2, POLRMT | HDAC6 645/4885CYP11B1 4792/4885CYP11B2 4843/4885 |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | HDAC6 3800/4885CYP11B1 3847/4885CYP11B2 3787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.